Delivery Order SPE2DB20D3101-SPE2DB23FRDV0
- Not listed
- This federal contract award is a delivery order valued at $25,563.63 issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of CAPLYTA 42 MG CAPSULE 30S, a pharmaceutical product, with a period of performance through March 19, 2025. The contract is a firm fixed-price arrangement with no set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract...
- This federal contract award, valued at $6,226.87, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CAPLYTA 42 MG CAPSULE 30S, a medication, with an ultimate completion date of April 24, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type, and there is no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp...
- This federal contract award, valued at $11,213.43, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of CAPLYTA 42 MG CAPSULE 30S, a pharmaceutical product, with a performance period ending on June 6, 2024. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,173.63, is for the delivery of CAPLYTA 42 MG CAPSULE 30S, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of March 27, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,171.22, is a delivery order for the provision of CAPLYTA 21 MG CAPSULE 30S. The contract is a firm fixed-price agreement with an ultimate completion date of April 14, 2025. This contract is not associated with any set-aside designation. AmerisourceBergen Drug Corp is the prime contractor, and...
- This federal contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,746.70 firm fixed-price delivery order is for the supply of CAPLYTA 42 MG CAPSULE 30S, a pharmaceutical product. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,839.70 firm fixed-price delivery order is for the supply of CAPLYTA 42 MG CAPSULE 30S, a pharmaceutical product. The contract has an ultimate completion date of February 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of CAPLYTA 42 MG CAPSULE 30S medical products. The $14,189.99 firm fixed price contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of May 28, 2024. The contract is a delivery order and does not have a set-aside designation. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $1,067.73, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of CAPLYTA 42 MG CAPSULE 30S, a pharmaceutical product, with a completion date of January 7, 2025. The contract is a Delivery Order under a Firm Fixed Price arrangement, and there is no set-aside designation noted. AmerisourceBergen holds a significant Indefinite...
- This federal contract award, valued at $2,439.95, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CAPLYTA 42 MG CAPSULE 30S, a medical product, and has an ultimate completion date of February 6, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type, and there is no set-aside designation. AmerisourceBergen holds a significant Indefinite...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB23FRDV0Delivery Order
This federal contract award, valued at $1,461.45, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CAPLYTA 42 MG Capsules, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of March 1, 2023. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a for-profit organization registered in the System for Award Management (SAM.gov) and has a significant Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000, covering similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 2/28/23 |